Raymond James & Associates Halozyme Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 273,591 shares of HALO stock, worth $17.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
273,591
Previous 146,261
87.06%
Holding current value
$17.5 Million
Previous $7.66 Million
104.39%
% of portfolio
0.01%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding HALO
# of Institutions
609Shares Held
126MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$785 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$380 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$222 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$218 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.93B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...